About RMi 
  Shenzhen Ruimeng Innovation biotechnology Co., Ltd. (RMi), located in Building D3, Phase II, Zhiyuan, Nanshan District, Shenzhen, is a pioneer, innovator and leading provider of IVD raw materials, regents, devices, and services. Our company manages three centers, including a high-tech R&D center, an o
pening-up GMP production plant, as well as a high-efficient business and operation center. After several years of investment and construction, our company now consists of four advanced technology platforms, including protein (eukaryotic and prokaryotic) purification platform, antibody (hybridoma and recombinant) production platform, IVD reagents (immunoassay-based and nucleic acid-based tests) development platform, and POCT device development platform. We pride ourselves on assembling a team with diverse background, international vision, and rich industrialization experience. We are deeply committed to focusing on the clinical unmet needs and providing innovative IVD solutions for cancer, autoimmunity, cardiovascular, inflammation, infection and other diseases.

  By empowering our creative “four-dimensional integrity” platform (IVD raw materials+ reagents+devices+services) and implementing ISO13485 and GMP quality management systems, we aims to serve health China, adhere to technology innovation, create highly reliable brands, and make contributions to the health and well-being of human society. 

 Antigen & Antibody Division 

  RMi The protein R&D team develops and produces high-quality recombinant proteins (cytokines, growth factors, various proteases) with independent core technologies. Through strict quality control and a large number of experimental data support, we ensure that the recombinant protein products produced have high purity, biological activity and stability, and provide high-quality products and technical services for scientific research, clinical diagnosis, and drug development.

 IVD Division 

  RMi antibody R&D team uses the international leading B cell cloning technology to produce antibodies with high specificity, high sensitivity and high stability Polyclonal and monoclonal antibodies, focusing on the research and development of diagnostic and therapeutic products for tumors, immune system diseases, cardiovascular and viruses (HIV, HAV, etc.); provide antibody products for IVD companies, medical institutions, pharmaceutical companies and scientific research units.

 CDMO Service Center 

      RMi strives to create medical devices based on the medical device registrant system In-vitro diagnostic reagents project commissioned research and development, process transformation, performance evaluation and verification, quality system construction and certification, clinical trials, registration applications, product commissioned production, compliance warehousing supply chain management and many other services as one of the in-vitro diagnostic reagent products CDMO A one-stop professional service platform, providing customers with innovative project research and development, clinical registration, large-scale production and other services.